Exenatide Lowered A1C

Change in A1C From Baseline (%)

–1.5

–1

–0.5

0

0.5

–0.9%

*

–0.6%

*

+0.1%

Placebo (N=483)

5 µg (N=480)

10 µg (N=483)

Reductions at 30 Weeks, Combined Pivotals (ITT), Baseline A1C = 8.4

* Statistically different from placebo

Previous slide

Next slide

Back to first slide

View graphic version